ACELRX PHARMACEUT. DL-01 (R5XA) — Net Asset Momentum
ACELRX PHARMACEUT. DL-01 (R5XA) recorded a net asset momentum of 112.9% as of December 2025, with net assets of €17.04 Million EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Check how tangible is ACELRX PHARMACEUT. DL-01's equity to evaluate the tangible quality of the company's equity base.
YoY Momentum
Current Net Assets
Years of Data
Country
ACELRX PHARMACEUT. DL-01 Net Asset Momentum (2021–2025)
This chart tracks ACELRX PHARMACEUT. DL-01's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is +112.9%, with net assets of €17.04 Million EUR as of December 2025. Read ACELRX PHARMACEUT. DL-01 (R5XA) financial obligations for a breakdown of total debt and financial obligations.
Annual Net Asset History for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below shows the complete annual net asset history for ACELRX PHARMACEUT. DL-01 from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see ACELRX PHARMACEUT. DL-01 market capitalisation.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | €17.04 Million | €29.72 Million | €12.68 Million | ▲ +112.9% |
| 2024 | €8.00 Million | €18.24 Million | €10.23 Million | ▼ -43.3% |
| 2023 | €14.11 Million | €20.39 Million | €6.29 Million | ▼ -35.3% |
| 2022 | €21.81 Million | €47.49 Million | €25.67 Million | ▲ +160.8% |
| 2021 | €-35.89 Million | €77.89 Million | €113.79 Million | — |